Nutriband (NASDAQ: NTRB) announced that the Costa Rica Ministry of Health has approved its line of kinesiology tapes for import and sale, with exclusive distribution partner Innomedica CCB overseeing and financing the regulatory process. The company plans to ramp up marketing efforts in partnership with Innomedica, targeting both its kinesiology tape products and mosquito repellent patch line following the approval.
To view the full press release, visit https://ibn.fm/LmF4t
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company’s website is www.nutriband.com . Any material contained in or derived from the Company’s websites or any other website is not part of this press release.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
NRx Pharmaceuticals (NASDAQ: NRXP) announced it received a letter from the FDA’s Bioequivalence Program stating no bioequivalence deficiencies were identified at…
NRx Pharmaceuticals (NASDAQ: NRXP) announced that minutes from a Type C meeting with the U.S.…
Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated commercial biotechnology company, reported financial results for the…
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful…
Voyager Acquisition (NASDAQ: “VACHU,” “VACH,” “VACHW”) announced that holders of 25,217,315 Class A ordinary shares — representing approximately 99.67%…
Oragenics (NYSE American: OGEN) announced it is exploring potential acquisitions of additional central nervous system…